[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE60141773D1 - Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren - Google Patents

Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren

Info

Publication number
DE60141773D1
DE60141773D1 DE60141773T DE60141773T DE60141773D1 DE 60141773 D1 DE60141773 D1 DE 60141773D1 DE 60141773 T DE60141773 T DE 60141773T DE 60141773 T DE60141773 T DE 60141773T DE 60141773 D1 DE60141773 D1 DE 60141773D1
Authority
DE
Germany
Prior art keywords
ligands
use process
similar receptor
great
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60141773T
Other languages
English (en)
Inventor
Alan Aderem
Fumitaka Hayashi
David M Underhill
Adrian Ozinsky
Kelly D Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Systems Biology
Original Assignee
Institute for Systems Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23094403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60141773(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Institute for Systems Biology filed Critical Institute for Systems Biology
Application granted granted Critical
Publication of DE60141773D1 publication Critical patent/DE60141773D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60141773T 2001-04-20 2001-07-20 Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren Expired - Lifetime DE60141773D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28547701P 2001-04-20 2001-04-20
PCT/US2001/022978 WO2002085933A1 (en) 2001-04-20 2001-07-20 Toll-like receptor 5 ligands and methods of use

Publications (1)

Publication Number Publication Date
DE60141773D1 true DE60141773D1 (de) 2010-05-20

Family

ID=23094403

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60141773T Expired - Lifetime DE60141773D1 (de) 2001-04-20 2001-07-20 Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren

Country Status (5)

Country Link
US (3) US7915381B2 (de)
EP (1) EP1379552B2 (de)
AT (1) ATE463505T1 (de)
DE (1) DE60141773D1 (de)
WO (1) WO2002085933A1 (de)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US8703146B2 (en) 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
EP1379552B2 (de) 2001-04-20 2014-11-19 The Institute for Systems Biology Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren
US9045727B2 (en) * 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
AU2003264724A1 (en) * 2002-09-03 2004-03-29 Fondation Eurovacc Flagellin peptides as adjuvants for vaccines
WO2004075865A2 (en) * 2003-02-27 2004-09-10 3M Innovative Properties Company Selective modulation of tlr-mediated biological activity
WO2004094671A2 (en) * 2003-04-22 2004-11-04 Coley Pharmaceutical Gmbh Methods and products for identification and assessment of tlr ligands
EP1617845A4 (de) * 2003-04-28 2006-09-20 3M Innovative Properties Co Zusammensetzungen und verfahren zur induktion von opioid-rezeptoren
AR045261A1 (es) * 2003-08-12 2005-10-19 3M Innovative Properties Co Compuestos que contienen imidazo quinolina o imidazo piridina sustituidos; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos inmunomoduladores
WO2005020999A1 (en) * 2003-08-27 2005-03-10 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
AU2004270201A1 (en) * 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
AU2004278014B2 (en) * 2003-10-03 2011-04-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
WO2005040208A2 (en) * 2003-10-21 2005-05-06 Androclus Therapeutics, Soa Peptides derived from heat shock proteins binding toll-like receptors 2 and 4 and their use
EP1689433B1 (de) * 2003-10-22 2010-06-30 ID Biomedical Corporation of Quebec Zusammensetzungen und verfahren zur aktivierung der eigenen und allergischen immunität
CA2545774A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
WO2005048945A2 (en) * 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
SG148201A1 (en) * 2003-11-25 2008-12-31 3M Innovative Properties Co Substituted imidazo ring systems and methods
JP2007517035A (ja) * 2003-12-29 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
EP1699788A2 (de) * 2003-12-30 2006-09-13 3M Innovative Properties Company Imidazochinolinyl-, imidazopyridinyl- und imidazonaphthyridinylsulfonamide
KR20050073865A (ko) * 2004-01-12 2005-07-18 대한민국(전남대학교총장) 비브리오 패혈증균 편모 구성인자 플라젤린을유효성분으로 함유하는 백신 보조제
AU2005228150A1 (en) * 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
JP2007535924A (ja) * 2004-05-07 2007-12-13 − グスタフ ユングレン、ハンス ワクチン用アジュバントとしてのフラジェリンの使用
DE102004024674A1 (de) * 2004-05-18 2005-12-15 Wolfgang Lorenz Mittel und Verfahren zur Diagnose, Prophylaxe und Therapie von Bindegewebserkrankungen
US8017779B2 (en) * 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006009832A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
WO2006038923A2 (en) * 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US8026366B2 (en) * 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006065280A2 (en) * 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
WO2006005004A2 (en) * 2004-06-30 2006-01-12 University Of Florida Research Foundation Inc. Materials and methods for enhancing nitrogen fixation in plants
US20090270443A1 (en) * 2004-09-02 2009-10-29 Doris Stoermer 1-amino imidazo-containing compounds and methods
US7404963B2 (en) * 2004-10-01 2008-07-29 The University Of South Florida Flagellin-based adjuvants and vaccines
EP1819364A4 (de) * 2004-12-08 2010-12-29 3M Innovative Properties Co Immunmodulatorische zusammensetzungen, kombinationen und verfahren
CA2589556A1 (en) * 2004-12-16 2006-08-03 Wake Forest University Health Sciences Use of flagellin in tumor immunotherapy
EP2460534A1 (de) 2004-12-22 2012-06-06 Cleveland Clinic Foundation Flagellinverwandte Polypeptide und deren Verwendungen
HU227285B1 (en) * 2004-12-29 2011-01-28 Mta Enzimologiai Intezet Modified flagellins and flagellar filaments useful as receptors and processes for producing same
US8034938B2 (en) 2004-12-30 2011-10-11 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
JP5543068B2 (ja) * 2004-12-30 2014-07-09 スリーエム イノベイティブ プロパティズ カンパニー キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
BRPI0606479A (pt) 2005-01-19 2008-03-11 Vaxinnate Corp composições; proteìnas de fusão; polipepitìdeos; e métodos para estimular uma resposta imune em um indivìduo
AU2006210392A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers
JPWO2006085411A1 (ja) * 2005-02-10 2008-06-26 国立大学法人 北海道大学 免疫応答を惹起するための新規アジュバントおよびその利用
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
US7700728B2 (en) * 2005-03-24 2010-04-20 Schering Corporation Use of chimeric receptors in a screening assay for identifying agonists and antagonists of cell receptors
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
JP2008538550A (ja) 2005-04-01 2008-10-30 コーリー ファーマシューティカル グループ，インコーポレイテッド ウイルス感染および腫瘍性疾患を処置するためのサイトカイン生合成の調節因子としての１−置換ピラゾロ（３，４−ｃ）環状化合物
DE102005020798A1 (de) * 2005-04-28 2006-11-02 Eberhard-Karls-Universität Tübingen Universitätsklinikum Verwendung von TLR- und/oder Nod2-Liganden zur Herstellung eines Arzneimittels zur Behandlung einer Krankheit des zentralen Nervensystems
KR100804507B1 (ko) 2005-05-17 2008-02-20 전남대학교산학협력단 플라젤린을 포함하는 천식 및 알레르기 질환 면역치료제
US8137930B2 (en) * 2005-10-28 2012-03-20 University Of Maryland, Baltimore Attenuated Salmonella enterica serovar paratyphi A and uses thereof
WO2007062043A1 (en) * 2005-11-23 2007-05-31 Coley Pharmaceutical Group Inc. Method of activating murine toll-like receptor 8
WO2007098371A2 (en) * 2006-02-16 2007-08-30 Wayne State University Use of flagellin to prevent and treat gram negative bacterial infection
CN106237316A (zh) * 2006-03-07 2016-12-21 法克斯因内特公司 包含血细胞凝集素的组合物、制造其的方法与使用其的方法
WO2008008432A2 (en) * 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
WO2008063369A2 (en) * 2006-11-01 2008-05-29 George Mason Intellectual Properties, Inc. Biomarkers for neurological conditions
EP2121734B1 (de) * 2007-02-09 2013-05-08 Industry Foundation of Chonam National University Modifiziertes flagellin mit verbesserter stimulierung des toll-like-rezeptors 5
US20100330190A1 (en) * 2007-12-17 2010-12-30 Compans Richard W Immunogenic compositions and methods of use thereof
WO2009082440A2 (en) * 2007-12-18 2009-07-02 Vaxinnate Corporation Compositions of toll-like receptor agonists and malaria antigens and methods of use
EP3115060A1 (de) 2008-04-18 2017-01-11 VaxInnate Corporation Flagellin deletionsmutanten und deren verwendung
PT2320948E (pt) 2008-08-01 2013-06-17 Cleveland Clinic Foundation Métodos para o tratamento de lesões por reperfusão
WO2010040096A2 (en) * 2008-10-03 2010-04-08 Emory University Methods for the treatment of graft-versus-host disease
WO2010080007A2 (ko) * 2009-01-09 2010-07-15 부산대학교 산학협력단 Ｔｏｌｌ 유사수용체２ 리간드로서 기능하는 그람양성균 유래의 리포단백질
WO2010107778A1 (en) 2009-03-18 2010-09-23 Wake Forest University Health Sciences Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa
US20100322957A1 (en) * 2009-05-22 2010-12-23 Aderem Alan A Secretion-related bacterial proteins for nlrc4 stimulation
WO2010141312A2 (en) 2009-06-01 2010-12-09 Wake Forest University Health Sciences Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
US20120171239A1 (en) 2009-09-03 2012-07-05 Mizel Steven B Immunogenic Conjugates for Producing Immune Responses to Drugs of Abuse and Methods of Use
EP2531207B1 (de) 2010-02-05 2019-10-30 Cornell University Verfahren und zusammensetzungen für eine krebs-immuntherapie mit flagellin-tumor-assoziierten antigen-fusions-protein exprimierenden tumorzellen
GB2481267B (en) * 2010-06-15 2016-04-20 Univ Leicester Assay for determining the risk of a toll-like receptor containing foodstuff for causing systemic inflammation in vivo
JP5746761B2 (ja) 2010-06-25 2015-07-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 気道感染症の処置のための方法及び医薬組成物
US9872895B2 (en) 2010-09-24 2018-01-23 Emory University TLR5 ligands, therapeutic methods, and compositions related thereto
BR112013017283A2 (pt) 2011-01-10 2016-10-25 Cleveland Biolabs Inc uso de agonista de receptor do tipo toll para tratamento de câncer
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
WO2013169382A1 (en) * 2012-05-07 2013-11-14 DePuy Synthes Products, LLC Methods and devices for treating intervertebral disc disease
WO2013177440A2 (en) * 2012-05-23 2013-11-28 The Board Of Trustees Of The Leland Stanford Junior University Ordered flagellin array as an immunostimulant
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
EP3632458A1 (de) 2013-07-26 2020-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Verbindungen und pharmazeutische zusammensetzungen zur behandlung von bakterieninfektionen
WO2016019034A1 (en) 2014-07-30 2016-02-04 Cleveland Biolabs, Inc. Flagellin compositons and uses
WO2016109002A2 (en) 2014-10-16 2016-07-07 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
SG11201704814SA (en) 2014-12-23 2017-07-28 4D Pharma Res Ltd Pirin polypeptide and immune modulation
LT3065748T (lt) 2014-12-23 2018-03-12 4D Pharma Research Limited Bacteroides thetaiotaomicron padermė ir jos panaudojimas uždegimo sumažinimui
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
SI3360559T1 (sl) 2015-06-15 2020-02-28 4D Pharma Research Limited Sestavki, ki vsebujejo bakterijske seve
MA51639A (fr) 2015-06-15 2020-04-15 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
ME03563B (de) 2015-06-15 2020-07-20 4D Pharma Res Ltd Zusammensetzungen mit bakterienstämmen
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
SI3209310T1 (en) 2015-11-20 2018-06-29 4D Pharma Research Limited Compositions containing bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
SG11201807195VA (en) 2016-03-04 2018-09-27 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
JP7221538B2 (ja) 2017-05-22 2023-02-14 フォーディー ファーマ リサーチ リミテッド 細菌株を含む組成物
EP3630942B1 (de) 2017-05-24 2022-11-30 4D Pharma Research Limited Zusammensetzungen mit bakterienstamm
JP6884889B2 (ja) 2017-06-14 2021-06-09 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
WO2018229236A2 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
RS61367B1 (sr) 2017-06-14 2021-02-26 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
EP3424524A3 (de) * 2017-07-04 2019-02-27 CureVac AG Neuartige nukleinsäuremoleküle
AR112565A1 (es) 2017-07-20 2019-11-13 Spogen Biotech Inc Polipéptidos bioactivos para mejorar la protección, crecimiento y productividad en plantas
KR102524577B1 (ko) 2019-04-22 2023-04-21 전남대학교산학협력단 플라젤린 융합 단백질 및 이의 용도
FR3114970B1 (fr) 2020-10-08 2023-06-30 Univ Tours Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires
US20240277801A1 (en) 2021-06-30 2024-08-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Aerosol composition for pulmonary delivery of flagellin
WO2024035137A1 (ko) * 2022-08-10 2024-02-15 주식회사 메디스팬 바실러스 서브틸리스 플라젤린 변이체 및 이의 용도
WO2024085375A1 (ko) * 2022-10-19 2024-04-25 전남대학교산학협력단 Tlr5 활성능을 가진 플라젤린 면역증강제 유도체의 진핵세포 발현시스템을 이용한 제조 및 응용

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194254A (en) * 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
US6130082A (en) * 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
US5612035A (en) * 1989-03-21 1997-03-18 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
US5614192A (en) * 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
KR0162259B1 (ko) * 1989-12-05 1998-12-01 아미 펙터 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
US5618533A (en) * 1992-02-11 1997-04-08 Yale University Flagellin-based polypeptides for the diagnosis of lyme disease
US5888810A (en) * 1993-11-12 1999-03-30 The United States Of America As Represented By The Secretary Of Agriculture Campylobacteri jejuni flagellin-escherichia coli LT-B fusion protein
US5420109A (en) * 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents
US5817308A (en) * 1994-02-14 1998-10-06 University Of Rochester Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
US6190657B1 (en) * 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
AU4070097A (en) * 1996-08-16 1998-03-06 Uab Research Foundation, The Mucosal immunogens for novel vaccines
US6797813B2 (en) * 1996-09-23 2004-09-28 Schering Corporation AK155 antibodies and binding fragments thereof
WO1998016247A1 (en) * 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
JP2002527494A (ja) * 1998-10-16 2002-08-27 ザ・ジェネラル・ホスピタル・コーポレイション 細胞内病原体を標的付ける光増感剤である複合体
ATE349526T1 (de) * 1999-05-25 2007-01-15 Immunex Corp Il-1 eta dna und polypeptide
US6740487B1 (en) * 1999-06-10 2004-05-25 University Of Iowa Research Foundation Variant TLR4 nucleic acid and uses thereof
WO2001083739A2 (en) * 2000-04-28 2001-11-08 Immunex Corporation Human pellino polypeptides
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
WO2002009748A1 (en) * 2000-07-31 2002-02-07 Yale University Innate immune system-directed vaccines
FR2812304B1 (fr) * 2000-07-31 2004-12-17 Bio Merieux Complexe de lipo-viro-particules, procede de preparation et applications
EP1379552B2 (de) 2001-04-20 2014-11-19 The Institute for Systems Biology Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren

Also Published As

Publication number Publication date
US7915381B2 (en) 2011-03-29
ATE463505T1 (de) 2010-04-15
WO2002085933A1 (en) 2002-10-31
US20030044429A1 (en) 2003-03-06
US9085616B2 (en) 2015-07-21
EP1379552B1 (de) 2010-04-07
US20110008318A1 (en) 2011-01-13
US20120269855A1 (en) 2012-10-25
EP1379552B2 (de) 2014-11-19
EP1379552A1 (de) 2004-01-14

Similar Documents

Publication Publication Date Title
DE60141773D1 (de) Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren
MY125202A (en) Vaccine
CY1119291T1 (el) Πολυσθενη αντισωματα και χρησεις για αυτα
ATE357930T1 (de) Immunmodulierende zusammensetzungen die eine an antigen gebundene immunstimulierende sequenz enthalten und deren verwendungen
WO2005037190A3 (en) Multiplex vaccines
MXPA04003333A (es) Remodelado y glicoconjugacion de peptidos.
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
EP1594536A4 (de) Adjuvante influenza-vakzine
TR200103574T2 (tr) Amid ikameli/katkılı imidazokinolinler
WO2004030608A3 (en) Nanoemulsion vaccines
ATE315405T1 (de) Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
MXPA05014016A (es) Proteinas portadoras para vacunas.
NZ508366A (en) Neisseria meningitidis antigens and compositions
BR0210225A (pt) Holotoxina do cólera imunogênica mutante, composição imunogênica, método para realçar a resposta imune de um hospedeiro vertebrado a um antìgeno, sequência de dna isolada e purificada, molécula de ácido nucleico, célula hospedeira, método para produzir uma holotoxina do cólera imunogênica mutante, e, uso de uma holotoxina do cólera mutante
PL375398A1 (en) Immunostimulatory nucleic acids
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
DK1353689T3 (da) Immuniseringspræparater og anvendelse deraf
WO2006028429A3 (en) Peptides for targeting the prostate specific membrane antigen
WO2004005476A3 (en) Nucleic acid compositions for stimulating immune responses
WO2003025119A3 (en) Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies
DE60315827D1 (de) Verbesserte polysaccharid- und glykokonjugat-vakzine
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
AU8727201A (en) Genes involved in intestinal inflammatory diseases and use thereof

Legal Events

Date Code Title Description
8363 Opposition against the patent